Prosecution Insights
Prosecution Insights
10 pending office actions • 2 clients • 8 examiners • 6 art units • 0 of 10 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 7 (70%) |
| No statute on record | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 3 | 58.0% | +40.0% |
| STAVROU, CONSTANTINA E | 1 | 44.2% | +36.3% |
| GROOMS, TIFFANY NICOLE | 1 | 59.1% | +46.3% |
| RAHMAN, MASUDUR | 1 | 71.3% | +32.3% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| BATES, KEENAN ALEXANDER | 1 | 46.2% | +75.8% |
| EBBINGHAUS, BRIANA NOEL | 1 | 62.3% | +61.4% |
| BRISTOL, LYNN ANNE | 1 | 63.5% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | BRISTOL, LYNN ANNE | 132d overdue |
| 17433812 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | EBBINGHAUS, BRIANA NOEL | 30d overdue |
| 18061824 | COMBINATION THERAPIES | CANELLA, KAREN A | 33d |
| 18420525 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | REDDIG, PETER J | — |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | STAVROU, CONSTANTINA E | — |
| 18009568 | ZBTB32 INHIBITORS AND USES THEREOF | RAHMAN, MASUDUR | — |
| 17602730 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | BATES, KEENAN ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | BRISTOL, LYNN ANNE | 132d overdue |
| 18148807 | TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR | REDDIG, PETER J | 66d overdue |
| 17433812 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | EBBINGHAUS, BRIANA NOEL | 30d overdue |
| 18061824 | COMBINATION THERAPIES | CANELLA, KAREN A | 33d |
| 18339565 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL | REDDIG, PETER J | 55d |
| 18420525 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | REDDIG, PETER J | — |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | STAVROU, CONSTANTINA E | — |
| 18162236 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | GROOMS, TIFFANY NICOLE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| University of Pennsylvania | 6 |
| Novartis | 4 |
| Art Unit | Apps |
|---|---|
| 1646 | 3 |
| 1632 | 2 |
| 1643 | 2 |
| 1637 | 1 |
| 1633 | 1 |
| 1631 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18420525 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | The Trustees of the University of Pennsylvania | REDDIG, PETER J | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | Novartis AG | STAVROU, CONSTANTINA E | 1632 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18339565 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL | The Trustees of the University of Pennsylvania | REDDIG, PETER J | 1646 | §103Other | Final Rejection | 55d | Pending | Jun 22, 2023 |
| 18162236 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | The Trustees of the University of Pennsylvania | GROOMS, TIFFANY NICOLE | 1637 | §103§112DP | Final Rejection | — | Pending | Jan 31, 2023 |
| 18148807 | TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR | The Trustees of the University of Pennsylvania | REDDIG, PETER J | 1646 | Other | Non-Final OA | 66d overdue | Pending | Dec 30, 2022 |
| 18009568 | ZBTB32 INHIBITORS AND USES THEREOF | Novartis AG | RAHMAN, MASUDUR | 1633 | §102§103 | Final Rejection | — | Pending | Dec 09, 2022 |
| 18061824 | COMBINATION THERAPIES | Novartis AG | CANELLA, KAREN A | 1643 | §102§103§112 | Non-Final OA | 33d | Pending | Dec 05, 2022 |
| 17602730 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | The Trustees of the University of Pennsylvania | BATES, KEENAN ALEXANDER | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 08, 2021 |
| 17433812 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | Novartis AG | EBBINGHAUS, BRIANA NOEL | 1632 | §103§112 | Non-Final OA | 30d overdue | Pending | Aug 25, 2021 |
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | The Trustees of the University of Pennsylvania | BRISTOL, LYNN ANNE | 1643 | §103§112Other | Non-Final OA | 132d overdue | Pending | Jun 07, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial